REPORT ID 6890

Global Hospital-acquired Pneumonia (HAP) Drugs Sales Market Report 2017

Publish Date
1-Nov-17
Pages
116
Format
Electronic (PDF)

In this report, the global Hospital-acquired Pneumonia (HAP) Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split global into several key Regions, with sales (K Pcs), revenue (Million USD), market share and growth rate of Hospital-acquired Pneumonia (HAP) Drugs for these regions, from 2012 to 2022 (forecast), covering
    United States
    China
    Europe
    Japan
    Southeast Asia
    India

Global Hospital-acquired Pneumonia (HAP) Drugs market competition by top manufacturers/players, with Hospital-acquired Pneumonia (HAP) Drugs sales volume, Price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including
    Pfizer
    GlaxoSmithKline
    Merck
    Mylan
    Novartis
    Teva Pharmaceutical Industries
    AstraZeneca
    Arsanis
    Combioxin
    Shinogi
    Sun Pharmaceutical Industries
    The Medicines Company
    Theravance Biopharma
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    Antibacterial
    Antiviral
    Antifungal
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Hospitals
    Clinics
    Other

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

Global Hospital-acquired Pneumonia (HAP) Drugs Sales Market Report 2017
1 Hospital-acquired Pneumonia (HAP) Drugs Market Overview
    1.1 Product Overview and Scope of Hospital-acquired Pneumonia (HAP) Drugs
    1.2 Classification of Hospital-acquired Pneumonia (HAP) Drugs by Product Category
        1.2.1 Global Hospital-acquired Pneumonia (HAP) Drugs Market Size (Sales) Comparison by Type (2012-2022)
        1.2.2 Global Hospital-acquired Pneumonia (HAP) Drugs Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 Antibacterial
        1.2.4 Antiviral
        1.2.5 Antifungal
    1.3 Global Hospital-acquired Pneumonia (HAP) Drugs Market by Application/End Users
        1.3.1 Global Hospital-acquired Pneumonia (HAP) Drugs Sales (Volume) and Market Share Comparison by Application (2012-2022)
        1.3.2 Hospitals
        1.3.3 Clinics
        1.3.4 Other
    1.4 Global Hospital-acquired Pneumonia (HAP) Drugs Market by Region
        1.4.1 Global Hospital-acquired Pneumonia (HAP) Drugs Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 United States Hospital-acquired Pneumonia (HAP) Drugs Status and Prospect (2012-2022)
        1.4.3 China Hospital-acquired Pneumonia (HAP) Drugs Status and Prospect (2012-2022)
        1.4.4 Europe Hospital-acquired Pneumonia (HAP) Drugs Status and Prospect (2012-2022)
        1.4.5 Japan Hospital-acquired Pneumonia (HAP) Drugs Status and Prospect (2012-2022)
        1.4.6 Southeast Asia Hospital-acquired Pneumonia (HAP) Drugs Status and Prospect (2012-2022)
        1.4.7 India Hospital-acquired Pneumonia (HAP) Drugs Status and Prospect (2012-2022)
    1.5 Global Market Size (Value and Volume) of Hospital-acquired Pneumonia (HAP) Drugs (2012-2022)
        1.5.1 Global Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2012-2022)
        1.5.2 Global Hospital-acquired Pneumonia (HAP) Drugs Revenue and Growth Rate (2012-2022)

2 Global Hospital-acquired Pneumonia (HAP) Drugs Competition by Players/Suppliers, Type and Application
     2.1 Global Hospital-acquired Pneumonia (HAP) Drugs Market Competition by Players/Suppliers
        2.1.1 Global Hospital-acquired Pneumonia (HAP) Drugs Sales and Market Share of Key Players/Suppliers (2012-2017)
        2.1.2 Global Hospital-acquired Pneumonia (HAP) Drugs Revenue and Share by Players/Suppliers (2012-2017)
    2.2 Global Hospital-acquired Pneumonia (HAP) Drugs (Volume and Value) by Type
        2.2.1 Global Hospital-acquired Pneumonia (HAP) Drugs Sales and Market Share by Type (2012-2017)
        2.2.2 Global Hospital-acquired Pneumonia (HAP) Drugs Revenue and Market Share by Type (2012-2017)
    2.3 Global Hospital-acquired Pneumonia (HAP) Drugs (Volume and Value) by Region
        2.3.1 Global Hospital-acquired Pneumonia (HAP) Drugs Sales and Market Share by Region (2012-2017)
        2.3.2 Global Hospital-acquired Pneumonia (HAP) Drugs Revenue and Market Share by Region (2012-2017)
    2.4 Global Hospital-acquired Pneumonia (HAP) Drugs (Volume) by Application

3 United States Hospital-acquired Pneumonia (HAP) Drugs (Volume, Value and Sales Price)
    3.1 United States Hospital-acquired Pneumonia (HAP) Drugs Sales and Value (2012-2017)
        3.1.1 United States Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2012-2017)
        3.1.2 United States Hospital-acquired Pneumonia (HAP) Drugs Revenue and Growth Rate (2012-2017)
        3.1.3 United States Hospital-acquired Pneumonia (HAP) Drugs Sales Price Trend (2012-2017)
    3.2 United States Hospital-acquired Pneumonia (HAP) Drugs Sales Volume and Market Share by Players
    3.3 United States Hospital-acquired Pneumonia (HAP) Drugs Sales Volume and Market Share by Type
    3.4 United States Hospital-acquired Pneumonia (HAP) Drugs Sales Volume and Market Share by Application

4 China Hospital-acquired Pneumonia (HAP) Drugs (Volume, Value and Sales Price)
    4.1 China Hospital-acquired Pneumonia (HAP) Drugs Sales and Value (2012-2017)
        4.1.1 China Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2012-2017)
        4.1.2 China Hospital-acquired Pneumonia (HAP) Drugs Revenue and Growth Rate (2012-2017)
        4.1.3 China Hospital-acquired Pneumonia (HAP) Drugs Sales Price Trend (2012-2017)
    4.2 China Hospital-acquired Pneumonia (HAP) Drugs Sales Volume and Market Share by Players
    4.3 China Hospital-acquired Pneumonia (HAP) Drugs Sales Volume and Market Share by Type
    4.4 China Hospital-acquired Pneumonia (HAP) Drugs Sales Volume and Market Share by Application

5 Europe Hospital-acquired Pneumonia (HAP) Drugs (Volume, Value and Sales Price)
    5.1 Europe Hospital-acquired Pneumonia (HAP) Drugs Sales and Value (2012-2017)
        5.1.1 Europe Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2012-2017)
        5.1.2 Europe Hospital-acquired Pneumonia (HAP) Drugs Revenue and Growth Rate (2012-2017)
        5.1.3 Europe Hospital-acquired Pneumonia (HAP) Drugs Sales Price Trend (2012-2017)
    5.2 Europe Hospital-acquired Pneumonia (HAP) Drugs Sales Volume and Market Share by Players
    5.3 Europe Hospital-acquired Pneumonia (HAP) Drugs Sales Volume and Market Share by Type
    5.4 Europe Hospital-acquired Pneumonia (HAP) Drugs Sales Volume and Market Share by Application

6 Japan Hospital-acquired Pneumonia (HAP) Drugs (Volume, Value and Sales Price)
    6.1 Japan Hospital-acquired Pneumonia (HAP) Drugs Sales and Value (2012-2017)
        6.1.1 Japan Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2012-2017)
        6.1.2 Japan Hospital-acquired Pneumonia (HAP) Drugs Revenue and Growth Rate (2012-2017)
        6.1.3 Japan Hospital-acquired Pneumonia (HAP) Drugs Sales Price Trend (2012-2017)
    6.2 Japan Hospital-acquired Pneumonia (HAP) Drugs Sales Volume and Market Share by Players
    6.3 Japan Hospital-acquired Pneumonia (HAP) Drugs Sales Volume and Market Share by Type
    6.4 Japan Hospital-acquired Pneumonia (HAP) Drugs Sales Volume and Market Share by Application

7 Southeast Asia Hospital-acquired Pneumonia (HAP) Drugs (Volume, Value and Sales Price)
    7.1 Southeast Asia Hospital-acquired Pneumonia (HAP) Drugs Sales and Value (2012-2017)
        7.1.1 Southeast Asia Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2012-2017)
        7.1.2 Southeast Asia Hospital-acquired Pneumonia (HAP) Drugs Revenue and Growth Rate (2012-2017)
        7.1.3 Southeast Asia Hospital-acquired Pneumonia (HAP) Drugs Sales Price Trend (2012-2017)
    7.2 Southeast Asia Hospital-acquired Pneumonia (HAP) Drugs Sales Volume and Market Share by Players
    7.3 Southeast Asia Hospital-acquired Pneumonia (HAP) Drugs Sales Volume and Market Share by Type
    7.4 Southeast Asia Hospital-acquired Pneumonia (HAP) Drugs Sales Volume and Market Share by Application

8 India Hospital-acquired Pneumonia (HAP) Drugs (Volume, Value and Sales Price)
    8.1 India Hospital-acquired Pneumonia (HAP) Drugs Sales and Value (2012-2017)
        8.1.1 India Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2012-2017)
        8.1.2 India Hospital-acquired Pneumonia (HAP) Drugs Revenue and Growth Rate (2012-2017)
        8.1.3 India Hospital-acquired Pneumonia (HAP) Drugs Sales Price Trend (2012-2017)
    8.2 India Hospital-acquired Pneumonia (HAP) Drugs Sales Volume and Market Share by Players
    8.3 India Hospital-acquired Pneumonia (HAP) Drugs Sales Volume and Market Share by Type
    8.4 India Hospital-acquired Pneumonia (HAP) Drugs Sales Volume and Market Share by Application

9 Global Hospital-acquired Pneumonia (HAP) Drugs Players/Suppliers Profiles and Sales Data
    9.1 Pfizer
        9.1.1 Company Basic Information, Manufacturing Base and Competitors
        9.1.2 Hospital-acquired Pneumonia (HAP) Drugs Product Category, Application and Specification
            9.1.2.1 Product A
            9.1.2.2 Product B
        9.1.3 Pfizer Hospital-acquired Pneumonia (HAP) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        9.1.4 Main Business/Business Overview
    9.2 GlaxoSmithKline
        9.2.1 Company Basic Information, Manufacturing Base and Competitors
        9.2.2 Hospital-acquired Pneumonia (HAP) Drugs Product Category, Application and Specification
            9.2.2.1 Product A
            9.2.2.2 Product B
        9.2.3 GlaxoSmithKline Hospital-acquired Pneumonia (HAP) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        9.2.4 Main Business/Business Overview
    9.3 Merck
        9.3.1 Company Basic Information, Manufacturing Base and Competitors
        9.3.2 Hospital-acquired Pneumonia (HAP) Drugs Product Category, Application and Specification
            9.3.2.1 Product A
            9.3.2.2 Product B
        9.3.3 Merck Hospital-acquired Pneumonia (HAP) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        9.3.4 Main Business/Business Overview
    9.4 Mylan
        9.4.1 Company Basic Information, Manufacturing Base and Competitors
        9.4.2 Hospital-acquired Pneumonia (HAP) Drugs Product Category, Application and Specification
            9.4.2.1 Product A
            9.4.2.2 Product B
        9.4.3 Mylan Hospital-acquired Pneumonia (HAP) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        9.4.4 Main Business/Business Overview
    9.5 Novartis
        9.5.1 Company Basic Information, Manufacturing Base and Competitors
        9.5.2 Hospital-acquired Pneumonia (HAP) Drugs Product Category, Application and Specification
            9.5.2.1 Product A
            9.5.2.2 Product B
        9.5.3 Novartis Hospital-acquired Pneumonia (HAP) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        9.5.4 Main Business/Business Overview
    9.6 Teva Pharmaceutical Industries
        9.6.1 Company Basic Information, Manufacturing Base and Competitors
        9.6.2 Hospital-acquired Pneumonia (HAP) Drugs Product Category, Application and Specification
            9.6.2.1 Product A
            9.6.2.2 Product B
        9.6.3 Teva Pharmaceutical Industries Hospital-acquired Pneumonia (HAP) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        9.6.4 Main Business/Business Overview
    9.7 AstraZeneca
        9.7.1 Company Basic Information, Manufacturing Base and Competitors
        9.7.2 Hospital-acquired Pneumonia (HAP) Drugs Product Category, Application and Specification
            9.7.2.1 Product A
            9.7.2.2 Product B
        9.7.3 AstraZeneca Hospital-acquired Pneumonia (HAP) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        9.7.4 Main Business/Business Overview
    9.8 Arsanis
        9.8.1 Company Basic Information, Manufacturing Base and Competitors
        9.8.2 Hospital-acquired Pneumonia (HAP) Drugs Product Category, Application and Specification
            9.8.2.1 Product A
            9.8.2.2 Product B
        9.8.3 Arsanis Hospital-acquired Pneumonia (HAP) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        9.8.4 Main Business/Business Overview
    9.9 Combioxin
        9.9.1 Company Basic Information, Manufacturing Base and Competitors
        9.9.2 Hospital-acquired Pneumonia (HAP) Drugs Product Category, Application and Specification
            9.9.2.1 Product A
            9.9.2.2 Product B
        9.9.3 Combioxin Hospital-acquired Pneumonia (HAP) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        9.9.4 Main Business/Business Overview
    9.10 Shinogi
        9.10.1 Company Basic Information, Manufacturing Base and Competitors
        9.10.2 Hospital-acquired Pneumonia (HAP) Drugs Product Category, Application and Specification
            9.10.2.1 Product A
            9.10.2.2 Product B
        9.10.3 Shinogi Hospital-acquired Pneumonia (HAP) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        9.10.4 Main Business/Business Overview
    9.11 Sun Pharmaceutical Industries
    9.12 The Medicines Company
    9.13 Theravance Biopharma

10 Hospital-acquired Pneumonia (HAP) Drugs Maufacturing Cost Analysis
    10.1 Hospital-acquired Pneumonia (HAP) Drugs Key Raw Materials Analysis
        10.1.1 Key Raw Materials
        10.1.2 Price Trend of Key Raw Materials
        10.1.3 Key Suppliers of Raw Materials
        10.1.4 Market Concentration Rate of Raw Materials
    10.2 Proportion of Manufacturing Cost Structure
        10.2.1 Raw Materials
        10.2.2 Labor Cost
        10.2.3 Manufacturing Process Analysis of Hospital-acquired Pneumonia (HAP) Drugs
    10.3 Manufacturing Process Analysis of Hospital-acquired Pneumonia (HAP) Drugs

11 Industrial Chain, Sourcing Strategy and Downstream Buyers
    11.1 Hospital-acquired Pneumonia (HAP) Drugs Industrial Chain Analysis
    11.2 Upstream Raw Materials Sourcing
    11.3 Raw Materials Sources of Hospital-acquired Pneumonia (HAP) Drugs Major Manufacturers in 2016
    11.4 Downstream Buyers

12 Marketing Strategy Analysis, Distributors/Traders
    12.1 Marketing Channel
        12.1.1 Direct Marketing
        12.1.2 Indirect Marketing
        12.1.3 Marketing Channel Development Trend
    12.2 Market Positioning
        12.2.1 Pricing Strategy
        12.2.2 Brand Strategy
        12.2.3 Target Client
    12.3 Distributors/Traders List

13 Market Effect Factors Analysis
    13.1 Technology Progress/Risk
        13.1.1 Substitutes Threat
        13.1.2 Technology Progress in Related Industry
    13.2 Consumer Needs/Customer Preference Change
    13.3 Economic/Political Environmental Change

14 Global Hospital-acquired Pneumonia (HAP) Drugs Market Forecast (2017-2022)
    14.1 Global Hospital-acquired Pneumonia (HAP) Drugs Sales Volume, Revenue and Price Forecast (2017-2022)
       14.1.1 Global Hospital-acquired Pneumonia (HAP) Drugs Sales Volume and Growth Rate Forecast (2017-2022)
       14.1.2 Global Hospital-acquired Pneumonia (HAP) Drugs Revenue and Growth Rate Forecast (2017-2022)
       14.1.3 Global Hospital-acquired Pneumonia (HAP) Drugs Price and Trend Forecast (2017-2022)
    14.2 Global Hospital-acquired Pneumonia (HAP) Drugs Sales Volume, Revenue and Growth Rate Forecast by Region (2017-2022)
       14.2.1 Global Hospital-acquired Pneumonia (HAP) Drugs Sales Volume and Growth Rate Forecast by Regions (2017-2022)
       14.2.2 Global Hospital-acquired Pneumonia (HAP) Drugs Revenue and Growth Rate Forecast by Regions (2017-2022)
       14.2.3 United States Hospital-acquired Pneumonia (HAP) Drugs Sales Volume, Revenue and Growth Rate Forecast (2017-2022)
       14.2.4 China Hospital-acquired Pneumonia (HAP) Drugs Sales Volume, Revenue and Growth Rate Forecast (2017-2022)
       14.2.5 Europe Hospital-acquired Pneumonia (HAP) Drugs Sales Volume, Revenue and Growth Rate Forecast (2017-2022)
       14.2.6 Japan Hospital-acquired Pneum